February 13th 2023
Although trilaciclib appears to reduce neutropenia following treatment with FOLFOXIRI and bevacizumab in patients with metastatic colorectal cancer, the phase 3 PRESERVE 1 trial will be stopped due to a lack of responses.
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
View More
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
View More
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
View More
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
10/13/2023-10/14/2023
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
View More
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
View More
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
View More
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
View More
8th Annual School of Gastrointestinal Oncology® (SOGO®)
05/06/23 8:00 AM – 5:00 PM EDT
View More
Expert Illustrations & Commentaries™: Targeting FGFR2b Overexpression in Advanced Gastric and GEJ Cancers
View More
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
View More
Clinical Vignettes™: Testing and Treatment Strategies in Cholangiocarcinoma
View More
Advances In™: The Role of NRG1 Fusions Across Tumor Types
View More
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
View More
Community Practice Connections™: 7th Annual School of Gastrointestinal Oncology®
View More
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
View More
Tanios S. Bekaii-Saab, MD, on Potential of Dual Targeting to Transform Treatment of HER2+ CRC
August 2nd 2022At 2022 ASCO, Tanios S. Bekaii-Saab, MD, reviews the MOUNTAINEER trial of trastuzumab plus tucatinib for HER2-positive metastatic colorectal cancer and foreshadows how an approved regimen may help improve outcomes in this patient population.
Neoadjuvant Immunotherapy Produces Promising Antitumor Response in Locally Advanced dMMR/MSI-H CRC
July 25th 2022Patients with mismatch repair deficient and/or microsatellite instability–high locally advanced colorectal cancer appear to derive promising benefit from treatment with neoadjuvant immune checkpoint inhibitors.
Richard Kim, MD, Discusses Key Findings With Pembrolizumab Plus Chemo in Metastatic MSS/pMMR CRC
June 13th 2022Richard Kim, MD, discussed key findings of the phase 1b KEYNOTE-651 trial, examining pembrolizumab plus standard chemotherapy in patients with microsatellite-stable or mismatch repair–proficient colorectal cancer.
Prolonged PFS Observed With Addition of Atezolizumab to FOLFOXIRI and Bevacizumab for Metastatic CRC
June 2nd 2022Atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and irinotecan resulted in a tolerable safety profile and improved progression-free survival vs the control regimen in patients with metastatic colorectal cancer.
Tucatinib Plus Trastuzumab Yields Positive Topline Data in Phase 2 MOUNTAINEER Trial for HER2+ mCRC
May 24th 2022In the phase 2 MOUNTAINEER trial, patients with previously treated HER2-positive metastatic colorectal cancer who were treated with tucatinib plus trastuzumab were shown to have an improved objective response rate.